{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:02:53Z","timestamp":1793692973844,"version":"4.5.1"},"reference-count":22,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,10,16]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>Survival in ET is superior to that of PV, regardless of mutational status, but remains inferior to the sex- and age-matched US population. JAK2\/CALR\/MPL mutational status is prognostically informative in PMF, regarding overall and leukemia-free survival.<\/jats:p>","DOI":"10.1182\/blood-2014-05-579136","type":"journal-article","created":{"date-parts":[[2014,7,18]],"date-time":"2014-07-18T22:36:33Z","timestamp":1405722993000},"page":"2507-2513","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":672,"title":["Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis"],"prefix":"10.1182","volume":"124","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[{"name":"Laboratorio Congiunto MMPC, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk R.","family":"Larson","sequence":"additional","affiliation":[{"name":"Department of Statistics and Bioinformatics,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Finke","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emnet A.","family":"Wassie","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Pieri","sequence":"additional","affiliation":[{"name":"Laboratorio Congiunto MMPC, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naseema","family":"Gangat","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajmonda","family":"Fjerza","sequence":"additional","affiliation":[{"name":"Laboratorio Congiunto MMPC, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alem A.","family":"Belachew","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terra L.","family":"Lasho","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhett P.","family":"Ketterling","sequence":"additional","affiliation":[{"name":"Division of Cytogenetics, Department of Laboratory Medicine, and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Curtis A.","family":"Hanson","sequence":"additional","affiliation":[{"name":"Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Finazzi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juergen","family":"Thiele","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[{"name":"Division of Hematology and Research Foundation, Papa Giovanni XXIII Hospital, Bergamo, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[{"name":"Laboratorio Congiunto MMPC, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2019111818524892300_B1","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","article-title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"issue":"25","key":"2019111818524892300_B2","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms.","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111818524892300_B3","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111818524892300_B4","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2019111818524892300_B5","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2019111818524892300_B6","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons.","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"2019111818524892300_B7","article-title":"Calreticulin mutations and long-term survival in essential thrombocythemia [published online ahead of print May 5, 2014].","author":"Tefferi","journal-title":"Leukemia"},{"key":"2019111818524892300_B8","article-title":"Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment [published online ahead of print April 15, 2014].","author":"Fu","journal-title":"Leukemia"},{"issue":"22","key":"2019111818524892300_B9","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis.","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2019111818524892300_B10","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients.","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"2019111818524892300_B11","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients [published online ahead of print February 19, 2014].","author":"Guglielmelli","journal-title":"Leukemia"},{"issue":"8","key":"2019111818524892300_B12","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 vs type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients.","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am J Hematol"},{"issue":"7","key":"2019111818524892300_B13","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/leu.2014.83","article-title":"Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact.","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"issue":"9501","key":"2019111818524892300_B14","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"issue":"5","key":"2019111818524892300_B15","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111818524892300_B16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/ajh.21543","article-title":"Prodromal myeloproliferative neoplasms: the 2008 WHO classification.","volume":"85","author":"Kvasnicka","year":"2010","journal-title":"Am J Hematol"},{"issue":"6","key":"2019111818524892300_B17","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"issue":"24","key":"2019111818524892300_B18","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1200\/JCO.2012.42.1925","article-title":"Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.","volume":"30","author":"Hultcrantz","year":"2012","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111818524892300_B19","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.","volume":"29","author":"Barbui","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111818524892300_B20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/ajh.23585","article-title":"Masked polycythemia vera (mPV): results of an international study.","volume":"89","author":"Barbui","year":"2014","journal-title":"Am J Hematol"},{"issue":"4","key":"2019111818524892300_B21","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.","volume":"29","author":"Gangat","year":"2011","journal-title":"J Clin Oncol"},{"issue":"14","key":"2019111818524892300_B22","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/124\/16\/2507\/1380193\/2507.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/124\/16\/2507\/1380193\/2507.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T18:09:53Z","timestamp":1717092593000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/124\/16\/2507\/33182\/Longterm-survival-and-blast-transformation-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,16]]},"references-count":22,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2014,10,16]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-05-579136","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,16]]}}}